Otsuka Pharmaceutical acquires Transcend Therapeutics in USD1.2B PTSD drug deal

USA—Japanese pharmaceutical giant Otsuka Pharmaceutical has signed an agreement to fully acquire Transcend Therapeutics through its subsidiary Otsuka America for up to USD1.225 billion.

The deal will see Otsuka pay Transcend shareholders USD700 million at closing, with a further USD525 million available in milestone payments tied to future sales targets.

Subject to standard conditions, the transaction is expected to close in the second quarter of 2026.

What Otsuka is buying

At the heart of the deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.

Founded in 2021 and headquartered in New York, Transcend developed TSND-201 as a rapid-acting neuroplastogen—a compound designed to promote the brain’s ability to reorganize its neural circuits, supporting memory formation and emotional regulation.

The drug works by targeting monoamine transporters for serotonin, norepinephrine, and dopamine, increasing their concentrations in the synaptic cleft and thereby enhancing neuroplasticity.

Unlike some psychiatric compounds, TSND-201 is not hallucinogenic.

Notably, positive Phase II results from the IMPACT 1 trial were published in JAMA Psychiatry in February 2026, and the FDA granted the drug breakthrough therapy designation in July 2025.

Transcend has since begun recruiting patients for a Phase III trial.

Why this deal matters

Otsuka President Makoto Inoue described TSND-201 as “a potential paradigm-shifting therapy in the field of psychiatry,” pointing to the limited treatment options currently available for PTSD patients.

By combining Otsuka’s established expertise in psychiatric and neurological medicine with Transcend’s novel approach, the company aims to accelerate the drug’s development in collaboration with regulators.

Beyond TSND-201, Transcend is also developing prodrug candidates to improve the drug’s efficacy, safety, and tolerability profile and is preparing an Investigational New Drug application submission to the FDA.

Otsuka’s broader expansion push

This acquisition is the latest in a string of strategic moves by Otsuka over the past year.

In July 2025, the Japanese pharmaceutical company struck a US613 million deal with Swedish biotech Cantargia for antibodies targeting autoimmune and inflammatory diseases.

In October, it acquired Asia-Pacific rights to a gene therapy asset from 4DMT for up to USD 420 million.

Then in November, the FDA approved Otsuka’s first-in-class drug Voyxact, a once-monthly injection for immunoglobulin A nephropathy (IgAN).

Closer to home, the FDA recently accepted for priority review Otsuka’s new drug application for centanafadine, an investigational once-daily extended-release capsule for attention-deficit hyperactivity disorder (ADHD).

Since July, Otsuka’s stock has climbed more than 64%.